Trastuzumab has been approved in the treatment of HER2-positive patients with breast cancer (BC) (Slamon et al., 2001; Piccart-Gebhart et al., 2005) and advanced gastric cancer (AGC) (Bang et al., 2010). Here, ERBB2 is linked to breast cancer.